Cargando…

Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes

OBJECTIVE: We aimed to identify the effect of an extended number of neoadjuvant chemotherapy (NAC) cycles on prognosis and surgical morbidity after interval debulking surgery (IDS) in patients with newly diagnosed advanced ovarian cancer. METHODS: Medical records of patients with advanced ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Nam Kyeong, Suh, Dong Hoon, Kim, Kidong, Kim, Yong Beom, No, Jae Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121047/ https://www.ncbi.nlm.nih.gov/pubmed/37083873 http://dx.doi.org/10.1371/journal.pone.0284753

Ejemplares similares

Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
por: Kim, Se Ik, et al.
Publicado: (2020)

Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer
por: Kim, Se Ik, et al.
Publicado: (2014)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Maximum daily dose of G-CSF is critical for preventing recurrence of febrile neutropenia in patients with gynecologic cancer: A case–control study
por: Kim, Nam Kyeong, et al.
Publicado: (2022)

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
por: Hue, Hyejeong, et al.
Publicado: (2019)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Role of limonin in anticancer effects of Evodia rutaecarpa on ovarian cancer cells
por: Bae, Jae Ryul, et al.
Publicado: (2020)

HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP
por: Suh, Dong Hoon, et al.
Publicado: (2023)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer
por: Hwang, Woo Yeon, et al.
Publicado: (2021)

Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
por: Kim, Kidong, et al.
Publicado: (2021)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)

Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?†
por: Kim, Hee Seung, et al.
Publicado: (2008)

Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2018)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study
por: Kim, Miseon, et al.
Publicado: (2019)

Mutually exclusive antiproliferative effect of cell line‐specific HOX inhibition in epithelial ovarian cancer cell lines: SKOV‐3 vs RMUG‐S
por: Kim, Miseon, et al.
Publicado: (2020)

Major clinical research advances in gynecologic cancer in 2011
por: Suh, Dong Hoon, et al.
Publicado: (2012)

Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center
por: Lee, Yong Jae, et al.
Publicado: (2018)

Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial
por: Park, Soo Jin, et al.
Publicado: (2020)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
por: Kim, Hee Seung, et al.
Publicado: (2016)

CA19-9 elevation in ovarian mature cystic teratoma: Discrimination from ovarian cancer – CA19-9 level in teratoma
por: Cho, Hye-yon, et al.
Publicado: (2013)

Early Assessment of Response to Neoadjuvant Chemotherapy with (18)F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
por: Chung, Young Shin, et al.
Publicado: (2020)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
por: Lim, Hyunji, et al.
Publicado: (2022)

Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
por: Lee, Yong Jae, et al.
Publicado: (2018)

Matched-Case Comparisons in a Single Institution to Determine Critical Points for Inexperienced Surgeons’ Successful Performances of Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Stage IA2-IIA Cervical Cancer
por: Suh, Dong Hoon, et al.
Publicado: (2015)

Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy
por: Hwang, Woo Yeon, et al.
Publicado: (2021)

Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer
por: Hwang, Woo Yeon, et al.
Publicado: (2022)

Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer
por: Lee, Maria, et al.
Publicado: (2016)

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
por: Chung, Young Shin, et al.
Publicado: (2018)

Risk Factor and Treatment of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Intraepithelial Neoplasia
por: Kim, Ju-Hyun, et al.
Publicado: (2022)

Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer
por: Kim, Yun-Ji, et al.
Publicado: (2018)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy
por: An, Ji Yeong, et al.
Publicado: (2013)

Use of a ring retractor to facilitate specimen removal in laparoscopic surgery
por: Hong, Deok Ho, et al.
Publicado: (2020)

Major clinical research advances in gynecologic cancer in 2012
por: Suh, Dong Hoon, et al.
Publicado: (2013)

Prognostic value of complete metabolic response on (18)F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_crudkpddsd4rl0kge6705n7dju